Letermovir

This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate patients

Latest news

CHMP backs MSD’s CMV infection treatment

Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved
Merck says drug for CMV in transplant patients hits targets

Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA.

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Pharma deals during October 2012

CMV) and related assets. Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Working together against COVID-19: Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19: Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?: Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....